BetterLife Pharma Inc. announce that it has closed a non-brokered private placement of 10% convertible debentures for principal[al amount of CAD 300,000 on January 2, 2024. The convertible debenture interest rate of 10%, will mature on June 30, 2025. The Convertible Debentures are convertible at the option of the holder into units of the Company, consisting of one common share and one share purchase warrant, at a conversion price of CAD 0.10 per unit.

Each share purchase warrant will have an exercise price of CAD 0.10 and will expire on December 31, 2025. The transaction included participation from Dr. Ahmad Doroudian, Chief Executive Officer of the Company who subscribed a total of CAD 125,000 principal amount of convertible debentures under the Offering.